TCGA-A2-A04T-01A-21R-A034-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 75
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- G2M_CHECKPOINT+0.570
- MYC_TARGETS_V1+0.550
- MYC_TARGETS_V2+0.500
- ALLOGRAFT_REJECTION+0.370
- MITOTIC_SPINDLE+0.290
- WNT_BETA_CATENIN_SIGNALING+0.270
- KRAS_SIGNALING_DN+0.230
- DNA_REPAIR+0.200
- PANCREAS_BETA_CELLS+0.200
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.390
- ANGIOGENESIS-0.350
- INTERFERON_ALPHA_RESPONSE-0.340
- ESTROGEN_RESPONSE_LATE-0.270
- APICAL_SURFACE-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.230
- PROTEIN_SECRETION-0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.220
- COAGULATION-0.210
- APOPTOSIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A1HJ-01A-11R-A13Q-07 | — | E | 0.821 |
| 2 | TCGA-56-6546-01A-11R-1820-07 | — | cohortMD1 | 0.807 |
| 3 | TCGA-A8-A07C-01A-11R-A034-07 | — | E | 0.803 |
| 4 | TCGA-AN-A0AT-01A-11R-A034-07 | — | E | 0.801 |
| 5 | C3N-02494 | — | cohortSQ2 | 0.801 |
| 6 | TCGA-AO-A124-01A-11R-A10J-07 | — | E | 0.799 |
| 7 | TCGA-A1-A0SP-01A-11R-A084-07 | — | E | 0.796 |
| 8 | de5a4588-05ec-461f-9235-90611b01f4b6 | — | — | 0.795 |
| 9 | 20030039.TNBC | — | E | 0.793 |
| 10 | TCGA-85-6560-01A-11R-1820-07 | — | cohortMD1 | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |